ArticlePsychopharmacology2009
The future of endocannabinoid-oriented clinical research after CB1 antagonists.
Article in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 169 citations in OpenAlex.
- The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.The international journal of neuropsychopharmacology · 2015Trial
- Involvement of the endocannabinoid system in reward processing in the human brain.Psychopharmacology · 2012Trial
- CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.The American journal of drug and alcohol abuse · 2012Trial
- Antagonist-elicited cannabis withdrawal in humans.Journal of clinical psychopharmacology · 2011Trial
- Randomized, controlled, double-blind trial of taranabant for smoking cessation.Psychopharmacology · 2010Trial
- Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.Current topics in behavioral neurosciences · 2026Review
- Cannabis use disorder: from neurobiology to treatment.The Journal of clinical investigation · 2024Review
- The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect.Pharmacology, biochemistry, and behavior · 2024Article
- Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory.Frontiers in pharmacology · 2024Article
- Microbiome variations induced by delta9-tetrahydrocannabinol predict weight reduction in obese mice.Frontiers in microbiomes · 2024Article
- Effects of β -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction.Current neuropharmacology · 2023Article
- Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy.Frontiers in nephrology · 2023Article
- Review
- Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.Translational psychiatry · 2022Article
- Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies.International journal of molecular sciences · 2022Review
- Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Functional Selectivity of a Biased Cannabinoid-1 Receptor (CBACS pharmacology & translational science · 2021Article
- Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors PossiblyFrontiers in pharmacology · 2021Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionGreat interest has been shown by the medical community and the public in the cannabinoid CB(1) receptor antagonists, such as rimonabant, for treatment of obesity, metabolic syndrome, and possibly drug addiction. DISCUSSION: This novel class of drug has therapeutic potential for other disorders, as the endocannabinoid system is involved in various health conditions. However, rimonabant, the first clinically available member of this class of drugs, has been linked to increased risk of anxiety, depression, and suicidality. Due to those risks, the European Medicines Agency called for its withdrawal from the market in October, 2008. Shortly after this decision, several pharmaceutical companies (Sanofi-aventis, Merck, Pfizer, Solvay) announced that they would stop further clinical research on this class of drug. Here, we provide an overview of those events and make several suggestions for continuing such clinical research, while safeguarding the safety of patients and clinical trial subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.